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OBJECTIVES: This study estimated the economic burden of atrial ﬁ brillation & ﬂ utter 
(AF) in Korea with societal perspective. METHODS: We identiﬁ ed patients who had 
at least three national health insurance (NHI) claims record with a primary or a 
secondary diagnosis of AF (ICD-10 codes: I48) in 2007. Health sector costs of the 
stroke were measured from the NHI PUKclaims records. Patient and family costs were 
estimated as transportation and cair-givers’ costs when admitting the hospitals and 
visiting the outpatient clinics and care-givers’ cost. The costs due to productivity loss 
were deﬁ ned as patients and caregivers productivity loss associated with outpatient 
visits or hospitalizations. RESULTS: A total of 56,499 AF patients were identiﬁ ed 
with prevalence for treatment of AF. The total cost of AF in the nation was estimated 
to be 589 billion Korean won (KRW) which included health sector cost at 41 billion 
KRW, patient/family cost at 8 billion KRW and cost due to productivity losses at 540 
billion KRW. The per-capita cost of stroke was 10 million KRW. CONCLUSIONS: 
AF is not only an important risk factor for stroke but also has signiﬁ cant economic 
burden as a single disease entity. The cost due to productivity losses were identiﬁ ed 
as the largest component of the overall economic burden. 
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OBJECTIVES: The current study was designed to calculate the direct cost of non-
compliance and the direct cost of undiagnosed diabetes and hypertension to US’s 
health system. Understanding these expenses can inform screening and education 
budget policy regarding expenditure levels that can be calculated to be cost-beneﬁ cial. 
METHODS: The study was conducted in three parts. First, a computer search was 
performed to get the numbers required for calculations. Second, a calculation formula-
tion was estimated for noncompliance and undiagnosed diabetes and hypertension. 
Third, calculation was undertaken in the light of the numbers and formulation previ-
ously obtained. RESULTS: Direct risk reduction caused by hypertension for stroke, 
heart attack, kidney disease and heart disease were calculated for 100% Compliant 
Strategy. Risk, case and cost reduction for 100% Compliant strategy were 32%, 8.5 
million and US$72 billion, respectively. Direct risk reduction caused by diabetes for 
eye diseases, kidney disease, stroke, heart disease, amputation were calculated for 
100% Compliant Strategy. Risk, case and cost reduction were calculated for 100% 
Compliant Strategy were 19%, 1 million and US$16.5 billion, respectively. CONCLU-
SIONS: The society; government, insurers, politicals and other stakeholders can spend 
up to these amounts in screening, education and prevention afforts in an effort to 
reduce these costly and traumatic sequale of noncompliant diabetes and hypertension 
patients. 
PCV14
COSTS OF INITIAL ISCHEMIC STROKE CARE
Kim SH1, Jo MW1, Kim EJ2, Kim HJ2, Yun SJ2
1University of Ulsan College of Medicine, Seoul, South Korea, 2Korea University, Seoul, South 
Korea
OBJECTIVES: The purpose of this study is to estimate the cost of ischemic stroke 
after its diagnosis and compare to its consecutive monthly costs for 1 year. METHODS: 
The study subjects were patients with an initial diagnosis (ICD code: I63). The data 
were obtained from National Health Insurance Corporation data, National health and 
nutrition examination survey and national statistics. We analyzed costs in societal 
perspective. Stroke costs are classiﬁ ed into direct medical costs, transportation and 
caregiver costs. RESULTS: Ischemic stroke costs for the initial month were ten times 
as much as the costs for the following successive month after diagnosis. In the ﬁ rst 
month, medical costs accounted for almost 90% of the total stroke costs. Inpatient 
costs and outpatient costs are occupied 55%, 33%, respectively. CONCLUSIONS: 
The stroke costs after initial diagnosis are substantial. The effort to reduce stroke costs 
and early detection for stroke can reduce the burden to society. 
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OBJECTIVES: Orthopedic surgery is one of the highest risk factors for venous throm-
boembolism. The main objective of this retrospective database analysis was to examine 
direct medical costs for pulmonary embolism (PE) in patient undergoing orthopedic 
surgery in Slovakia from the payer perspective. METHODS: A retrospective database 
analysis of biggest health insurance company in Slovakia was conducted. Resources 
used and their respective costs in connection with PE were collected for patients 
undergoing elective total hip replacement (THR) or elective total knee replacement 
(TKR) during the period from January 1, 2008 until January 1, 2009. All resources 
and costs were categorized in four groups: inpatient, outpatient, drugs and examina-
tions. Costs in Euro were calculated with ofﬁ cial exchange rate 30,126 Sk/f. Cost 
comparison between groups of patients with PE and without PE after orthopedic 
surgery was done. RESULTS: The group of 3008 patients (995 men and 2013 women) 
after elective orthopedic surgery was analyzed. There were 2325 patients with THR 
and 993 with TKR. Twelve cases of PE which were hospitalized, were identiﬁ ed in 
the whole group. Average direct medical costs for group of patients hospitalized for 
pulmonary embolism were f3909 with the following structure of costs: inpatient—
f2442; outpatient—f168; drugs—f552; examinations—f747, respectively. CONCLU-
SIONS: Average direct medical costs for patients with PE after elective orthopedic 
surgery were f3909 in 2008. This is f724 more then the average direct medical costs 
for patients without PE. 
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OBJECTIVES: The incidence of acute coronary syndrome (ACS) in the Czech Republic 
is 3248 cases/million/year (CZECH registry) and belongs to the most frequent causes 
of hospitalizations. The aim was to assess and compare costs and length-of-stay in 
patients with STEMI and non-STEMI in the Faculty Hospital in the Czech Republic 
from payer’s perspective. METHODS: Retrospectively tracked data were clinical 
characteristics, medication, stay in standard cardiology unit (SCU) and/or intensive 
care unit (ICU) and revascularization procedures in patients hospitalized with STEMI 
or non-STEMI in specialized center for patients with ACS. Inpatient care costs include 
ﬂ at rate of admission, examinations, stay in monitored bed, drugs and particularly 
coronary angiography and percutaneous coronary intervention (PCI) (25.5CZK = 
1EUR). RESULTS: Total 385 patients (mean age 63.9 years; 75.6% male; 61% 
hypertensive) were evaluated, 54.5% of patients with STEMI and 45.5% of patients 
with non-STEMI. 15.1% of patients had MI in anamnesis and 9% of patients were 
treated previously PCI. The coronary angiography was performed during hospitaliza-
tion in 95% of patients; revascularization by PCI with stent implantation was in 
71.9% of patients (86.2% STEMI and 54.9% non-STEMI; P < 0.001); 10.9% were 
treated by coronary-artery bypass (5.2% STEMI and 17.7% non-STEMI; P < 0.001). 
The mean length-of-stay was 5.7 days (5.9 days STEMI and 5.5 days non-STEMI; P 
= 0.033) with mean total cost f3597.5 (f4288.7 STEMI and f2768.0 non-STEMI; P 
< 0.001). 77.1% of patients were in need of ICU on an average 2.3 days. The mean 
rate of PCI was f3380. CONCLUSIONS: Acute coronary syndromes present substan-
tial medical, social, and economic burden worldwide in particular due to high preva-
lence and expensive treatment procedures. In our study the cost of PCI formed around 
85% of a total inpatient cost in both STEMI and non-STEMI. 
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OBJECTIVES: Cardiovascular diseases are the leading cause of morbidity and mortal-
ity in the world. Coronary angiography remains the corner stone in the management 
of CVD, and the gold standard for CAD diagnosis The coronary angiography is 
performed to diagnose the presence and severity of CAD. Globally, diagnostic cardiac 
catheterization ranks as the sixth most commonly performed health-care procedure 
with total charges exceeding $4 billion annually. This high volume makes the coronary 
angiography a subject of interest to all health-care manager, health economist and 
clinicians. The Objective of this study is to utilize the Step Down costing methodology 
for estimating the cost of Coronary Angiography at UKMMC. METHODS: This is a 
cross sectional study, using random sampling with 303 patients who have undergone 
Coronary Angiography as inpatient at UKMMC, between January 2003 till December 
2005. The sample is grouped using International Reﬁ ned DRG (IR-DRG) to assign 
DRG to each patient. Step down costing is done to cost these Coronary Angiography 
patients using Clinical Cost Modeling (CCM) software Ver. 2.1. Costing tool gives us 
the cost per day of stay in the Cardiology ward. Once related to the Length of Stay 
(LOS) cost of entire inpatient care episode were estimate. The cost of a procedure at 
the catheterization lab (CathLab) was calculated using the step down methodology. 
Cost of the inpatient Coronary Angiography is calculated by summation of CathLab 
cost and cost of inpatient episode of care. RESULTS: Cost of Inpatient Coronary 
Angiography at UKMMC ranges from RM 1007 to RM 16,697.26 (mean = RM 
5,110.89, SD RM 2,798.06). Cost per procedure in CathLab is estimated to be RM 
384. The total cost of treatment for 303 patients is RM 82,115. CONCLUSIONS: 
Step Down Costing using the CCM is an easy way estimating the cost of one of the 
high volume procedure. This can help devising strategies for better utilization of scarce 
health-care resources. 
